CALCIMEDICA

The CalciMedica team is comprised of scientists, physicians, drug development experts and entrepreneurs dedicated to the development of CRAC channel inhibitors for acute and chronic inflammatory conditions... CalciMedica's current drug development efforts build on nearly two decades of research into the role of CRAC channels in the immune response as well as preclinical and clinical research demonstrating the potential therapeutic benefit of CRAC channel inhibitors in life-threatening inflammatory diseases. CalciMedica was founded in 2007 by Dr. Ken Stauderman and colleagues from TorreyPines Therapeutics, along with a team from Harvard's CBR Institute for Biomedical Research. Dr. Stauderman is a world leader in CRAC channel biology and pharmacology... CalciMedica, Inc., is focused on further developing Auxora™, to treat life-threatening inflammatory diseases, such as acute pancreatitis (AP), asparaginase-induced pancreatic toxicity (AIPT), acute kidney injury (AKI), and acute..

Also known as: CalciMedica Inc.

Primary location: La Jolla United States